Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin

• US 6,613,804 B2
• Filed: 12/04/2001
• Issued: 09/02/2003
• Est. Priority Date: 05/20/1993
• Status: Expired due to Fees

• Current Assignee: Encysive Pharmaceuticals Incorporated (Pfizer Inc.)
• Original Assignee: Encysive Pharmaceuticals Incorporated (Pfizer Inc.)
• Inventors: Kois, Adam, Chan, Ming Fai, Kogan, Timothy, Balaji, Vitukudi Narayanaiyengar, Verner, Erik Joel
• Primary Examiner(s): Lambkin, Deborah C.
• Application Number:
  US10/006,256
• Publication Number:
  US 20020095041A1
• Time in Patent Office: 637 Days
• Field of Search: 564/84, 514/601
• US Class Current: 514/601
• CPC Class Codes: C07D 261/14 Nitrogen atoms
• CPC Class Codes: C07D 261/16 Benzene-sulfonamido isoxazoles
• CPC Class Codes: C07D 413/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 413/14 containing three or more hetero rings

Abstract

Biphenylsulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, bicyclic or tricyclic carbon or heterocyclic ring biphenylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

Claims

1. A compound that has formula I:

or a pharmaceutically acceptable salt or ester thereof, wherein;

Ar¹ is a bicyclic or tricyclic carbon or heterocyclic ring;

Ar² has formula (I);

wherein;

Ar² is substituted with one or more than one substituent, each of which is selected independently from the selections set forth for R²⁶ and R¹³, in which

R²⁶ and R¹³ are each independently selected from H, OH, OHNH, NH₂, NO₂, halide, pseudohalide, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heterolaryl, alkoxy, alkylamino, dialkylamino, alkylthio, haloalkoxy, haloalkyl, alkylsulfinyl, alkylsulfonyl, aryloxy, arylamino, arylthio, arylsulfinyl, arylsulfonyl, haloalkyl, haloaryl, alkoxycarbonyl, carbonyl, alkylcarbonyl, aminocarbonyl, arylcarbonyl, formyl, substituted or unsubstituted amido, substituted or unsubstituted ureido, in which the alkyl, alkenyl and alkynyl portions contain from 1 up to about 14 carbon atoms, and are either straight or branched chains or cyclic, and the aryl portions contain from about 4 to about 16 carbons, with the proviso that if there is only one R¹³, it is not hydrogen.

2. The compounds of claim 1, in which R²⁶ and R¹³ are each independently selected from H, loweralkyl, haloalkyl and halide.

3. The compounds of claim 1, in which at least one substituent R¹³ is in the para position.

4. A pharmaceutical composition, comprising one or more compounds of claim 1 in a pharmaceutically acceptable carrier.

5. A method for the treatment of endothelin-mediated diseases, comprising administering an effective amount of one or more compounds of claim 1, wherein the effective amount is sufficient to ameliorate one or more of the symptoms of the disease.

6. The method of claim 5, wherein the disease is selected from the group consisting of hypertension, cardiovascular disease, asthma, pulmonary hypertension, inflammatory diseases, ophthalmologic disease, menstrual disorders, obstetric conditions, wounds, gastroenteric disease, renal failure, immunosuppressant-mediated renal vasoconstriction, erythropoietin-mediated vasoconstriction, endotoxin shock, pulmonary hypertension, anaphylactic shock and hemorrhagic shock.

7. The method of claim 5, wherein the disease is selected from the group consisting of hypertension, cardiovascular disease, pulmonary hypertension, erythropoietin-mediated vasoconstriction, endotoxin shock, pulmonary hypertension, anaphylactic shock and hemorrhagic shock.

8. The method of claim 5, wherein the disease is selected from the group consisting of asthma and inflammatory diseases.

9. A method for inhibiting the binding of an endothelin peptide to endothelin_A (ET_A) or endothelin_B (ET_B) receptors, comprising contacting the receptors an endothelin peptide and with one or more compounds of claim 1, wherein:

the contacting is effected prior to, simultaneously with or subsequent to contacting the receptors with the endothelin peptide.

10. A method for altering endothelin receptor-mediated activity, comprising contacting endothelin receptors with one or more compounds of claim 1.

11. A pharmaceutical composition formulated for single dosage administration, comprising an effective amount of one or more compounds of claim 1, wherein the amount is effective for ameliorating the symptoms of an endothelin-mediated disease.

12. An article of manufacture, comprising packaging material and one or more compounds of claim 1 contained within the packaging material, wherein the compound is effective for antagonizing the effects of endothelin, ameliorating the symptoms of an endothelin-mediated disorder, or inhibiting the binding of an endothelin peptide to an ET receptor with an IC₅₀ of less than about 10 μ

M, and the packaging material includes a label that indicates that the sulfonamide or salt thereof is used for antagonizing the effects of endothelin, inhibiting the binding of endothelin to an endothelin receptor or treating an endothelin-mediated disorder.

13. The compounds of claim 1 in which the alkyl, alkenyl and alkynyl portions contain from 1 up to about 6 carbon atoms.

14. The compounds of claim 1 in which the aryl portions contain from about 4 to about 10 carbons.